Preliminary Investigation About Hematokrit Forecast of Chemotherapy Tolerance of Lung Cancer Patients
-
摘要:目的
通过探讨血常规中粒红系各指标在化疗后的变化，以期找到预测化疗耐受性的相关指标。
方法回顾性分析311例肺癌患者资料，录入病例资料及血液常规各指标，建立数据库，并对数据进行单因素和多因素变量Spearman相关分析。
结果所有患者中，贫血分析显示：化疗后发生贫血的总周期数为1 269（83.60%）、无贫血的为249（16.40%），其中发生轻度贫血的总周期数为1 100（86.68%）、中度贫血的为155（12.21%）、重度贫血的为12（0.95%）、极重度贫血的为2（0.16%）。本研究将总周期数定义为血液化验的总数目，其中各指标异常的数目为阳性表达。红细胞计数、血红蛋白、红细胞压积以及平均红细胞体积阳性表达在不同程度贫血之间不同，差异有统计学意义（P < 0.05）。单因素分析显示：病理类型、肿瘤分期、性别及化疗周期与化疗干预后外周血相关粒红系阳性表达发生存在密切关系（P < 0.05）。Spearman相关性分析显示：中性粒细胞百分比、红细胞计数、血红蛋白及红细胞压积之间存在相关性，化疗耐受性与红细胞计数、血红蛋白、红细胞压积存在相关性，红细胞压积是化疗耐受性预测的独立因素。
结论红细胞压积对预测肺癌患者化疗耐受性有一定的价值。
Abstract:ObjectiveTo investigate blood index changes after chemotherapy of patients in lung cancer, in order to find relevant index to predict tolerance of chemotherapy.
MethodsA retrospective analysis of 311 cases of lung cancer patients. Input case data and blood routine index, set up the database, and analyse the data by single factor and multi-factor variable Spearman correlation.
ResultsIn all patients, Anemia analysis showed that the total number of cycles of anemia after chemotherapy account for 1 269(83.60%), without anemia was 249 cycles (16.40%), including the total number of cycles of mild anemia after chemotherapy account for mild anemia 1 100 (86.68%), moderate anemia cycles 155 (12.21%), severe anemia cycles 12 (0.95%), and extremely severe anemia cycles was 2 (0.16%). and there are statistically significant in which positive expression of red blood cell count, hemoglobin, hematocrit, and mean corpuscular volume is different between different degrees of anemia. Single factor analysis showed that pathological type, tumor stage, gender, and chemotherapy cycle were closely related to the positive expression of peripheralblood associated granulocyte and erythroid (P < 0.05), which was statistically significant. Spearman correlation analysis showed that there was a correlation between the percentage of neutrophils, red blood cell count, hemoglobin and hematocrit, and there was a correlation between chemotherapy tolerance and red blood cell count, hemoglobin, hematocrit. Hematocrit is a independent factor for prediction of chemotherapy tolerance.
ConclusionHematocrit has a certain value in predicting lung cancer patients' chemotherapy tolerance.
-
Key words:
- Lung cancer /
- Anemia /
- Related factor /
- Chemotherapy tolerance /
- Correlation
-
-
表 1 NCI标准评判贫血程度时肺癌中各指标表达情况
Table 1 The expression of each index in lung cancer accordance with the classification criteria of NCI
下载: 导出CSV
表 2 红细胞压积标准评判贫血程度时肺癌中各指标表达情况
Table 2 The expression of each index in lung cancer accordance with the classification criteria of hematocrit
下载: 导出CSV
-
[1] DeSantis C, Naishadham D, Jemal A, et al. Cancer statistics for African Americans, 2013[J]. CA Cancer J Clin, 2013, 63(3): 151-66. doi: 10.3322/caac.21173
[2] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. doi: 10.3322/caac.v61:2
[3] Wernyj RP, Morin PJ. Molecular mechanisms of plati-num resistance: still searching for the Achilles' heel[J]. Drug Resist Updat, 2004, 7(4-5): 227-32. doi: 10.1016/j.drup.2004.08.002
[4] 王新帅, 秦玲, 高社干, 等. rhG-CSF对TP方案化疗后骨髓抑制的有效性和安全性研究[J].中国现代药物应用, 2011, 5(16): 7-8. http://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY201116005.htm Wang XS, Qin L, Gao SG, et al. Analysis of efficacy and safety of rhG-CSF used for myelosuppression patients after chemotherapy with TP program[J]. Zhongguo Xian Dai Yao Wu Ying Yong, 2011, 5(16): 7-8. http://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY201116005.htm
[5] 盖绿华, 冯其梅, 左大鹏, 等.中性粒细胞缺乏伴发热与感染鉴别诊断及治疗[J].中华医院感染学杂志, 2013, 23(5): 1027-9. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201305033.htm Gai LH, Feng QM, Zuo DP, et al. Differentiation between neutropenia complicated by fever and infections and the treatment[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2013, 23(5): 1027-9. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201305033.htm
[6] 汪变红, 张明智, 付晓瑞, 等.化放疗骨髓抑制机制及防治研究进展[J].肿瘤基础与临床, 2013, 26(2): 162-5. http://www.cnki.com.cn/Article/CJFDTOTAL-HLZL201302025.htm Wang BH, Zhang MZ, Fu XR, et al. Bone marrow inhibition mechanism and research progress of prevention and cure of the radiotherapy[J]. Zhong Liu Ji Chu Yu Lin Chuang, 2013, 26(2): 162-5. http://www.cnki.com.cn/Article/CJFDTOTAL-HLZL201302025.htm
[7] Mäenpää J, Puistola U, Riska H, et al. Impact of Epoetin-beta on Anemia and Health-related Quality of Life in Cancer Patients: A Prospective Observational Study Using the Generic 15D Instrument[J]. Anticancer RES, 2014, 34(5): 2325-9.
[8] Harada H. How can we overcome tumor hypoxia in radiation therapy?[J]. J Radiat Res, 2011, 52(5): 545 -56. doi: 10.1269/jrr.11056
[9] Qiu MZ, Yuan ZY, Luo HY, et al. Impact of pretreatment hemato-logic profile on survival of colorectal cancer patients[J]. Tumour Biol, 2010, 31(4): 255-60. doi: 10.1007/s13277-010-0024-x
[10] Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients[J]. Eur Cancer, 2004, 40(15): 2293-306. doi: 10.1016/j.ejca.2004.06.019
[11] 王剑, 马若冰, 陈雪琴.晚期非小细胞肺癌患者贫血相关因素及其对预后的影响[J].肿瘤学杂志, 2013, 19(9): 718-21. http://www.cnki.com.cn/Article/CJFDTOTAL-XHON201309017.htm Wang J, Ma RB, Chen XQ. Correlative factors of Anemia in advanced non-small cell lung cancer patients and its impact on prognosis[J]. Zhong Liu Xue Za Zhi, 2013, 19(9): 718-21. http://www.cnki.com.cn/Article/CJFDTOTAL-XHON201309017.htm
[12] Weiss G, Goodnough LT. Anemia of chronic disease[J]. New Engl Med, 2005, 352(10): 1011-23. doi: 10.1056/NEJMra041809
[13] 王莹, 燕丽香, 陈文彰.恶性肿瘤贫血相关因素分析[J].中国医药导刊, 2013, 15(7): 1156-7. http://www.cnki.com.cn/Article/CJFDTOTAL-DKYY201307032.htm Wang Y, Yan LX, Chen WZ. Analysis of anemia relevant factors in cancer patients[J]. Zhongguo Yi Yao Dao Kan, 2013, 15(7): 1156-7. http://www.cnki.com.cn/Article/CJFDTOTAL-DKYY201307032.htm
[14] Wan S, Lai Y, Myers RE, et al. Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies -results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers[J]. BMC Cancer, 2013, 13: 340. doi: 10.1186/1471-2407-13-340
[15] Holgersson G, Sandelin M, Hoye E, et al. Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lungcancer[J]. Med Oncol, 2012, 29(5): 3176-82. doi: 10.1007/s12032-012-0247-3
[16] 吴飞雪.化疗前后肿瘤性贫血的变化与疗效的关系及相关因素分析[J].中国当代医药, 2013, 20(19): 41-4. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201319022.htm Wu FX. Relationship between changes of cancer-related anemia pre and post chemotherapy and therapeutic effect and analysis of its relevant factors[J]. Zhongguo Dang Dai Yi Yao, 2013, 20(19): 41-4. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201319022.htm
[17] 魏玮, 何俊民, 王理伟, 等.肿瘤相关性贫血铁代谢情况与生活质量相关性的研究[J].临床肿瘤学杂志, 2009, 14(4): 350-3. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL200904019.htm Wei W, He JM, Wang LW, et al. Study on the relationship between iron metabolism situation and the quality of life in tumou associated anemia patients[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2009, 14(4): 350-3. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL200904019.htm
[18] Verbeke N, Beguin Y, Wildiers H, et al. High prevalence ofanemia and limited use of therapy in cancer patients: a Belgian survey (Anemia Day 2008)[J]. Support Care Cancer, 2012, 20(1): 23-8. doi: 10.1007/s00520-010-1045-0
计量
- 文章访问数: 1802
- HTML全文浏览量: 335
- PDF下载量: 518
